Extraordinary Preclinical Outcomes for Stroke Treatment

 An injectable compound that is currently in a Phase 1 human safety clinical trial was shown in animal studies to repair the devastating brain damage caused by stroke. It even worked a full week after the onset of a stroke. In other words, human victims might someday be able to regain or improve bodily functions using this new stroke treatment, including key cognitive abilities. The remarkable discovery that a faulty central nervous system can be repaired at a cellular level in trial animals is the subject of a white paper study that was just published in the peer-reviewed scientific publication...READ MORE

FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

AstraZeneca and Merck, known as MSD outside the United States and Canada announced that a supplemental New Drug Application for LYNPARZA in combination with abiraterone and prednisone or prednisolone has been accepted and granted priority review by the U.S. Food and Drug Administration for the treatment of adult patients with metastatic castration-resistant prostate cancer...READ MORE

GSK Completes Acquisition of Affinivax, Inc.

GSK plc announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge (Boston, Massachusetts). Affinivax has pioneered the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. As previously announced, the acquisition of Affinivax aligns with GSK’s strategy of building a strong portfolio of specialty medicines and vaccines...READ MORE

Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases

Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases. ADX-914 is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP. Q32 has recently completed a biomarker-enabled Phase 1 study characterizing pharmacokinetics, pharmacodynamics and safety of ADX-914 that demonstrated pharmacological effect on T cells...READ MORE

National Occupational Standards Now Available

BioTalent Canada has launched its first 45 National Occupational Standards for Canada’s bio-economy. These standards were validated by industry stakeholders and will replace BioTalent Canada’s Skills Profiles and Skills At-A-Glances. The NOS profiles indicate what skills, education, and credentialing are required to perform a specific role. Companies will use these standards for more effective recruitment, professional development, succession planning, and compensation benchmarking...READ MORE

Roche Launches New Diagnostic Test for the Better Understanding of Immune Response to SARS-CoV-2

Roche announced the launch of the Elecsys® IGRA SARS-CoV-2 test in countries that accept the CE Mark1. The Elecsys IGRA SARS-CoV-2 test supports the better understanding of immune response to SARS-CoV-2 infection and vaccination. The test will be an additional tool to make better-informed decisions around care, sanitary measures and treatment options. This will be particularly important for at-risk patient groups.nWith the transition from a pandemic to an endemic state of COVID-19, there is an increasing need to better understand the adaptive response of the human immune system to SARS-CoV-2...READ MORE

Ondine Biomedical Completes Patient Recruitment for US Phase II Nasal Photodisinfection Trial

Ondine Biomedical Inc. has recruited the final patient to its nasal photodisinfection exploratory Phase 2 trial. The trial is evaluating how effectively Ondine’s nasal photodisinfection technology eradicates pathogens – specifically Staphylococcus aureus – in the nose. The single-center, BENEFIT-aPDT open-label study is being carried out at HCA Healthcare’s Memorial Health University Medical Center in Savannah, Georgia, and has recruited over 300 patients...READ MORE

Lipid Nanoparticles that Enable COVID-19 mRNA Vaccines

The team of Pieter Cullis, Michael Hope and Thomas Madden have worked together for approximately 40 years. They are receiving a Governor General’s Innovation Award for their work in developing lipid nanoparticle (LNP) systems to deliver cancer drugs to tumours and to enable RNA and DNA based drugs to be used therapeutically...READ MORE

Senior Manager Technical Marketing

Evonik’s Health Care Drug Delivery & Medical Device Solutions Product Line provides polymeric and lipid-based parenteral drug delivery solutions to life science and pharmaceutical industries by offering contract development and clinical and commercial phase GMP-compliant manufacturing services (CDMO), as well as advanced processing equipment technologies under the brand name LIPEX®. This position will support the services-based business and promote its growth to ensure the Parenteral Drug Delivery Solutions Segment and the Vancouver site (VAN) are recognized as the leading CDMO by the pharmaceutical industry for polymeric, liposomal and lipid nanoparticle (LNP) drug development and product.

LEARN MORE

Research & Development Chemist

Alpha-9 is seeking a Research & Development Chemist to join our growing organization. The ideal candidate will have experience with solid-phase peptide synthesis, and preferably with radiopharmaceutical development. This person will be responsible for designing, planning and synthesizing peptides/peptidomimetic building blocks and precursors for radiopharmaceutical product candidates. 

We are an early-stage company, so you will have the opportunity to participate cross-functionally and contribute to the build-out and set-up of new laboratory facilities. The ideal candidate will have multi-tasking ability and a desire to strive in a fast-paced environment. 

LEARN MORE

Tenure-Track Assistant Professor Position, Pharmacology

We now invite applications for a full-time tenure-track Assistant Professor position in Pharmacology. Applicants for this position must possess a PhD or equivalent doctoral qualification, with research expertise that broadens our current strengths in cancer pharmacology, cardiovascular pharmacology, diabetes, drug metabolism/pharmacokinetics, neuropharmacology, and pharmacogenomics or complements these strengths with a research focus in pharmacology.

LEARN MORE

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, they are expediting development of our diverse pipeline of novel therapeutics through their own capabilities and collaborations.



Visit Website

NanoVation Therapeutics (NTx) is an early-stage gene therapy company developing next-generation platform technologies utilizing lipid nanoparticles for the safe and efficient delivery of nucleic acids to a variety of tissues. Focused on translating personalized gene therapies to the clinic, NTx aims to treat and prevent multiple age-related diseases enabling a healthier tomorrow, TODAY.

Visit Website